Search
Rallybio Corp
RLYBAdd to Watchlist
16.610USD
-0.250-1.48%
Close 09-24 16:00（ET）
88.03MMarket Cap
LossP/E TTM
About Rallybio Corp Company
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Rallybio Corp Profile
Ticker SymbolRLYB
Company nameRallybio Corp
IPO dateJul 29, 2021
CEOUden (Stephen)
Number of employees25
Security typeOrdinary Share
Fiscal year-endJul 29
Address234 Church Street
CityNEW HAVEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06510
Phone12038593820
Websitehttps://rallybio.com/
Ticker SymbolRLYB
IPO dateJul 29, 2021
CEOUden (Stephen)
Company Executives of Rallybio Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
446.42K
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
446.42K
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
446.42K
--
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
182.48K
+49.29%
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
182.48K
+49.29%
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
182.48K
+49.29%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
48.81K
+91.57%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
48.81K
+91.57%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
48.81K
+91.57%
Dr. Hui Liu, Ph.D.
Dr. Hui Liu, Ph.D.
Independent Director
Independent Director
20.96K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
446.42K
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
446.42K
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
446.42K
--
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
182.48K
+49.29%
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
182.48K
+49.29%
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
182.48K
+49.29%
FAQs
Who are the top five shareholders of Rallybio Corp?
The top five shareholders of Rallybio Corp are: Mr. Ronald M. (Ron) Hunt
How many institutions hold shares of Rallybio Corp (RLYB)?
As of 2026Q1, 138 institutions hold shares of Rallybio Corp, with a combined market value of approximately 3.48M, accounting for 65.82% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -412366.00.